Aclaris Therapeutics, Inc. — Director's Dealing 2021

Apr 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-04-22

Reporting Person: Ruffo Frank (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-22	Common Stock	S	30000	$26.8406	Disposed	209059	Direct
2021-04-23	Common Stock	S	29200	$26.6369	Disposed	179859	Direct
2021-04-23	Common Stock	S	800	$27.3287	Disposed	179059	Direct
2021-04-26	Common Stock	S	27239	$25.7933	Disposed	151820	Direct
2021-04-26	Common Stock	S	100	$26.44	Disposed	151720	Direct

Footnotes

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.23 to $27.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.23 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.38 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.